Lipolysis, GH secretagogues, and adipose tissue modulation in obesity models

Weight loss peptide research focuses primarily on compounds that either directly promote lipolysis (fat breakdown) or stimulate growth hormone (GH) secretion, which secondarily drives fat oxidation. AOD-9604 is a modified fragment of the C-terminal portion of human growth hormone (hGH 176–191) that retains the lipolytic activity of GH without its proliferative or diabetogenic effects. CJC-1295 with DAC (Drug Affinity Complex) is a GHRH (growth hormone-releasing hormone) analogue with extended half-life due to albumin binding. Ipamorelin is a selective GH secretagogue that stimulates pulsatile GH release without the cortisol/prolactin side-effects of first-generation GHRPs.

Mechanism

AOD-9604 activates β3-adrenergic receptors in adipose tissue, stimulating lipolysis via cAMP/PKA-mediated phosphorylation of hormone-sensitive lipase (HSL), without binding the IGF-1 receptor. CJC-1295 DAC binds GHRH receptors on pituitary somatotrophs, driving GH synthesis and release; DAC modification enables albumin binding that extends half-life to 6–8 days. Ipamorelin mimics ghrelin at the GHS-R1a receptor, producing selective, pulsatile GH release with minimal effect on ACTH, cortisol, or prolactin.

Plain-language summary

Weight loss peptide research centres on compounds that either directly break down fat cells or stimulate the body's own growth hormone — which drives fat burning, lean mass preservation, and metabolic health. AOD-9604 is an engineered fragment of human growth hormone designed specifically to activate fat-cell breakdown (lipolysis) without the blood sugar dysregulation or anabolic side-effects of full-length HGH. CJC-1295 and Ipamorelin are studied in combination: CJC-1295 signals the pituitary gland to produce more growth hormone, while Ipamorelin amplifies the resulting pulse — producing up to 5× more GH than either compound alone, with a highly selective profile that avoids the cortisol and prolactin increases seen with older GH-releasing peptides. Together, these compounds represent a sophisticated approach to metabolic research that goes well beyond simple calorie restriction.

Research protocols

Protocol	Peptides	Duration	Dosage	Endpoint
Diet-Induced Obesity Model (DIO)	AOD-9604	42 days	250 µg/kg (rodent) · Once daily SC injection	Body weight (twice weekly), fat mass % (DXA or MRI), adipose tissue lipolysis (glycerol release from explants), serum lipid profile (triglycerides, FFA)
GH Secretion Pulse Study	CJC-1295 DAC, Ipamorelin	28 days	CJC-1295: 300 µg/kg; Ipamorelin: 100 µg/kg · CJC-1295 DAC once weekly; Ipamorelin once daily	GH serum pulsatility (serial sampling every 20 min over 4 hours), IGF-1 serum (ELISA), body composition by DXA at days 0 and 28

Key studies

1998

AOD9604: An anti-obesity drug which acts on the β3-adrenoceptor

AOD9604 stimulated lipolysis in adipocytes exclusively via β3-adrenergic receptors without detectable IGF-1 receptor binding, demonstrating a cleaner metabolic profile than full-length hGH in DIO rat models.

PMID 9497040

2006

Long-acting growth hormone-releasing hormone analogue (CJC-1295) stimulates growth hormone and insulin-like growth factor-I secretion

A single injection of CJC-1295 produced GH secretion lasting 6 days and dose-dependent increases in serum IGF-1 of 2–3×, demonstrating the utility of albumin-binding for sustained GHRH-receptor agonism.

PMID 16352683

Verdict

✓Pros

AOD-9604 received FDA GRAS (Generally Recognised As Safe) status for oral use — favourable regulatory safety signal
CJC-1295 DAC requires only once-weekly dosing due to its 6–8 day half-life — highly convenient vs. daily protocols
Ipamorelin is the most selective GH secretagogue available: no cortisol, prolactin, or ACTH elevation at standard doses
CJC-1295 has published Phase I and II human trial data with well-characterised GH/IGF-1 pharmacokinetics
AOD-9604 selectively activates β3 receptors in fat cells without binding IGF-1 receptors — no anabolic side-effects
Combination of CJC-1295 + Ipamorelin produces 2–5× greater GH pulse than either compound alone

×Cons

All three compounds require subcutaneous injection — no oral route with established human bioavailability
CJC-1295 substantially raises IGF-1 levels: blood glucose monitoring is advisable, especially for pre-diabetic individuals
AOD-9604 Phase III obesity trials showed limited efficacy at the doses tested orally — systemic injectable effects differ
Body composition improvements require consistent use over weeks to months — not a rapid intervention
EU availability is currently limited: only Particle Peptides consistently stocks all three in 2026
GH elevation during sleep can disrupt sleep architecture if dosed too close to bedtime

Legal status

AOD-9604 is unscheduled and not a controlled substance in the EU. CJC-1295 and Ipamorelin are on the WADA Prohibited List (S2 — Peptide Hormones) for competitive athletes. They are not approved medicines in the EU or USA. Purchase as research compounds is legal in most EU countries for non-competitive research purposes. Athletes subject to testing should be aware of detection windows.

FAQ

Does AOD-9604 affect blood glucose like GH?

No. AOD-9604 was specifically engineered to lack the diabetogenic and anabolic effects of full-length GH. It does not bind the IGF-1 receptor or significantly alter fasting glucose in published studies, which is a key safety advantage in obesity research.

Why combine CJC-1295 with Ipamorelin rather than use either alone?

CJC-1295 (GHRH analogue) and Ipamorelin (GHS-R agonist) act via distinct receptor pathways that converge on somatotroph GH release. Their combination produces synergistic GH secretion (2–5× AUC vs. monotherapy) while Ipamorelin's selectivity keeps cortisol and prolactin elevations minimal.